Brief: Nanobiotix Announces 18.1 Month Median Overall Survival For 41 Evaluable Elderly, Frail Patients With HNSCC In Phase I Expansion Evaluating Nbtxr3
24/10/2021 22:04
Oct 24 (Reuters) - Nanobiotix SA NANOB.PA :
* NANOBIOTIX ANNOUNCES 18.1 MONTH MEDIAN OVERALL SURVIVAL
FOR 41
EVALUABLE ELDERLY, FRAIL PATIENTS WITH HNSCC IN PHASE I
EXPANSION EVALUATING NBTXR3
* NBTXR3 ADMINISTRATION WAS FEASIBLE AND WELL TOLERATED IN
POPULATION WITH SIGNIFICANT BURDEN OF DISEASE AND COMORBIDITY
Source text for Eikon: ID:nBwbFYRDsa
Further company coverage: NANOB.PA
((reuters.briefs@thomsonreuters.com;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering